Direct answer (40-60 words)
Zepbound (tirzepatide) produced an average 20.9% body-weight loss at the 15 mg dose over 72 weeks in the SURMOUNT-1 trial. Most of the loss happens between months 3 and 12. About 36% of patients lost at least 25% of their starting weight. Results vary, and weight regain after stopping is common without continued treatment.
Table of contents
- The 30-second answer
- What the SURMOUNT-1 trial actually showed
- Month-by-month timeline of expected results
- What % of patients hit each weight-loss milestone
- Real changes in body measurements, not just the scale
- Zepbound vs Wegovy: head-to-head data
- What happens when you stop: the regain question
- Factors that predict above- or below-average results
- The before-and-after photo problem (and what to look for)
- Side effects during the loss curve
- FAQ
- Footer disclaimers
What the SURMOUNT-1 trial actually showed
SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022) is the registration trial that put tirzepatide on the map for weight loss. Roughly 2,539 adults with obesity or overweight plus a weight-related condition were randomized to placebo or one of three tirzepatide doses (5 mg, 10 mg, 15 mg weekly) for 72 weeks.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Average body-weight reduction at week 72:
| Dose | Average weight loss | % who lost >5% | % who lost >10% | % who lost >15% | % who lost >20% | % who lost >25% |
|---|---|---|---|---|---|---|
| 5 mg | 15.0% | 85% | 69% | 50% | 32% | 15% |
| 10 mg | 19.5% | 89% | 78% | 64% | 48% | 28% |
| 15 mg | 20.9% | 91% | 83% | 71% | 57% | 36% |
| Placebo | 3.1% | 35% | 19% | 9% | 3% | 1.5% |
For an adult starting at 230 pounds on the 15 mg dose, average loss landed near 48 pounds. About 1 in 3 people on 15 mg lost 25% of their starting weight or more. About 1 in 10 on 15 mg lost less than 5%, which is the threshold most clinicians use to define a meaningful response.
That last number matters. Tirzepatide is the strongest weight-loss medication on the market, and roughly 9% of people on it still don't get a clinically meaningful response. If you're a non-responder, you'll usually know by month 3 to 4.
Month-by-month timeline of expected results
Zepbound uses a slow titration schedule. The dose escalates every 4 weeks until you reach your target maintenance dose. This means early-month results look small, and patients who stop at month 1 because "it isn't working" usually quit before the medication has reached therapeutic doses.
A realistic month-by-month progression for a patient on the standard titration heading to 15 mg:
Month 1 (2.5 mg starter dose). This is a tolerance dose. It's not designed to produce weight loss. Most patients lose 1 to 3% of body weight, mostly from reduced appetite and changing food preferences. For a 230-pound starting weight, that's 2 to 7 pounds.
Month 2 (5 mg). First therapeutic dose. Average loss accelerates. Cumulative loss at week 8 is typically 4 to 6%. For 230 pounds, that's 9 to 14 pounds total.
Month 3 (7.5 mg). Cumulative loss around 7 to 9% for the average patient. By week 12 in SURMOUNT-1, 67% of 15-mg-arm patients had already lost 5% or more. This is the point where clothes fit differently and other people start to notice.
Month 4 (10 mg). Cumulative loss around 10 to 12%. The pace remains steady through this stretch. Body composition starts to shift visibly, especially in the face and abdomen.
Month 5 (12.5 mg). Cumulative loss around 13 to 15%. Some patients plateau briefly here as the body adjusts to the new metabolic set point. Brief plateaus during titration are normal and not a sign that the medication has stopped working.
Month 6 (15 mg, maintenance). Cumulative loss around 14 to 17%. Most of the visible "before and after" change has now happened. Waist, neck, and face measurements show the largest absolute changes.
Months 7 to 12. The curve flattens. Loss continues but at a slower pace, around 0.5 to 1% per month for responders. Cumulative loss at month 12 averages 18 to 20% for 15-mg patients.
Months 12 to 18. The slowest phase. Most patients reach their personal nadir somewhere between month 14 and 18, then plateau. Average cumulative loss in SURMOUNT-1 at week 72 (about 16.5 months) was 20.9% on 15 mg.
Beyond 18 months. The data gets thinner, but extension studies suggest patients who stay on a maintenance dose hold their loss within ~2% of nadir for at least 2 years.
The shape of this curve is steep early, then gradually flatter. If you graph weight against time, the slope is steepest between months 3 and 9, which is when most of the visible change happens.
What % of patients hit each weight-loss milestone
People search "Zepbound before and after" looking for a specific outcome they can compare themselves to. The honest answer is a distribution, not a single number. Here's the SURMOUNT-1 distribution at 72 weeks for the 15 mg arm:
- 9% lost less than 5% (non-responders)
- 8% lost 5 to 10%
- 12% lost 10 to 15%
- 14% lost 15 to 20%
- 21% lost 20 to 25%
- 36% lost 25% or more
About 1 in 3 people on the maximum dose loses a quarter of their body weight or more. About 1 in 10 doesn't respond meaningfully. The rest land somewhere in the middle.
Predictors of being in the top tier of responders (the 25%+ group):
- Higher starting BMI (more weight to lose)
- Younger age
- Longer time at the 15 mg maintenance dose
- Combined with structured nutrition and resistance training
- Female sex (small effect, not large)
Predictors of being in the lower tier:
- Type 2 diabetes (responders still lose weight, just somewhat less on average)
- Long history of weight cycling
- Concurrent medications that promote weight gain (some antipsychotics, steroids, beta-blockers)
- Inability to tolerate dose escalation past 5 mg
Real changes in body measurements, not just the scale
The scale captures one number, and it's not the most useful one for visible change. SURMOUNT-1 also tracked:
| Measurement | Average change at 15 mg |
|---|---|
| Waist circumference | -7.2 inches |
| Hip circumference | -5.1 inches |
| Neck circumference | -1.8 inches |
| Waist-to-hip ratio | -0.04 |
| Systolic blood pressure | -8.0 mmHg |
| Diastolic blood pressure | -4.7 mmHg |
| Triglycerides | -24% |
| HbA1c (in pre-diabetic patients) | -0.5 percentage points |
| Liver fat (subset analysis) | -50% in patients with NAFLD |
Two of these matter for the "before and after" question specifically. Waist loss runs faster than total body weight loss, in percentage terms, because tirzepatide preferentially mobilizes visceral fat. A patient who loses 15% of body weight often loses 20% of their waist measurement. That's why the visual change in photos can look bigger than the scale number suggests.
Face changes ("Ozempic face" or its tirzepatide equivalent) usually appear by month 4. The technical reason is that subcutaneous fat depletion in the cheeks and temporal fossa happens at a similar pace to whole-body fat loss, but face changes are more obvious in photos than abdominal changes covered by clothing.
Zepbound vs Wegovy: head-to-head data
SURMOUNT-5 (Aronne et al., New England Journal of Medicine, 2025) compared tirzepatide directly to semaglutide 2.4 mg over 72 weeks in 751 adults with obesity. Results:
| Outcome | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |
|---|---|---|
| Average weight loss | 20.2% | 13.7% |
| % achieving >25% loss | 32% | 16% |
| Waist reduction | 7.2 inches | 5.1 inches |
| Discontinuation rate | 6% | 8% |
Tirzepatide produced about 47% more relative weight loss than semaglutide in this head-to-head trial. Both medications were generally well tolerated, with semaglutide showing slightly higher rates of GI side effects.
For patients comparing options: tirzepatide has the better efficacy data. Semaglutide has more years of post-marketing safety data. Compounded versions of both are available through telehealth platforms while shortages persist.
What happens when you stop: the regain question
This is the most important part of the before-and-after conversation, and the part most marketing skips.
SURMOUNT-4 (Aronne et al., JAMA, 2024) addressed it directly. After an open-label 36-week tirzepatide lead-in, patients were randomized to either continue tirzepatide or switch to placebo for 52 more weeks. Results:
- Patients who continued tirzepatide: lost an additional 5.5% (total 25.3% loss from baseline)
- Patients who switched to placebo: regained roughly 14% of their lost weight within the 52-week off-drug period (net loss from baseline ended at about 9.9%)
Translation: stopping the medication does not reverse all of your loss, but it reverses a meaningful portion. After a year off-drug, the average patient kept about half of their initial loss. Some kept much more, some kept much less.
Why does regain happen? Two mechanisms:
- Appetite returns to baseline. The medication's primary effect is appetite suppression. Without it, hunger signals return to pre-treatment levels.
- Metabolic adaptation. Body weight loss of 20%+ reduces resting metabolic rate by 200 to 400 calories per day, even after accounting for lower body weight. This adaptation persists for months to years after weight loss.
The clinical implication: tirzepatide is a chronic-disease medication, like statins or blood-pressure drugs, not a temporary weight-loss intervention. Patients who plan a finite course should plan a structured off-ramp with continued nutrition and resistance training to minimize regain.
A reasonable off-ramp protocol:
- Stay at maintenance dose for at least 6 months after reaching nadir
- Taper rather than stop abruptly (drop one dose level every 4 to 6 weeks)
- During taper and after, prioritize protein intake (1.6 g/kg of goal body weight) and 2 to 3 resistance training sessions per week
- Monitor weight weekly and re-engage at the first sign of regain past 5% of nadir
Factors that predict above- or below-average results
Patients who lose more than the trial average tend to share some characteristics:
Starting habits. Patients who already had reasonable nutrition habits before starting tirzepatide tend to lose more, because the appetite suppression compounds with already-good food choices. Patients with severe dietary patterns (high fast-food, high sugar-sweetened-beverage intake) get a smaller bonus from the medication because their baseline was lower.
Resistance training. Patients who do 2 to 3 resistance training sessions per week lose less muscle and more fat. Body composition changes are more dramatic, and the visible "before and after" looks better at any given total weight loss.
Sleep and stress. Both affect cortisol and the appetite hormones tirzepatide modulates. Patients with fragmented sleep (under 6 hours) or chronic high stress tend to plateau earlier and at higher weights.
Adherence to dose escalation. Patients who tolerate escalation to 10 mg or 15 mg lose substantially more than patients who stay at 2.5 mg or 5 mg. About 30% of patients can't tolerate escalation past 7.5 mg due to GI side effects. They still lose meaningful weight (10 to 12% on average) but not the headline 20%+ numbers.
Concurrent medications. Some prescriptions counteract weight loss: insulin (especially in type 2 diabetes), some atypical antipsychotics, certain antidepressants (mirtazapine in particular), corticosteroids, and beta-blockers. A medication review with a clinician can sometimes identify a switchable drug.
Genetic variation. GLP-1 receptor sensitivity varies between individuals. There's no commercial test for it, but it's the most likely reason for the 9% non-response rate seen in the trial.
The before-and-after photo problem (and what to look for)
Search results for "Zepbound before and after" return thousands of social media photos. The honest framing for any of them:
- Lighting, posture, and clothing make as much difference as 10 pounds of weight loss in a side-by-side photo
- Some photos are real; some are old photos of the same person at different points in their weight history
- Influencer accounts often pair Zepbound photos with sponsored content; selection bias is heavy
- Time stamps matter: a "6-month transformation" at 15 mg shows substantially more change than a "6-month transformation" that includes 4 weeks at 2.5 mg
What to look for in trustworthy before-and-after content:
- Posted dates more than 12 months after starting
- Includes the dose escalation timeline, not just the start and end
- Mentions side effects honestly
- Mentions diet and exercise context
What to discount:
- Single-photo "after" with no time anchor
- Pairing with discount codes or affiliate links
- Photos of someone other than the account owner
Side effects during the loss curve
The rate of GI side effects roughly tracks the steepness of the loss curve. Most reports of nausea, constipation, and reflux happen during the first 8 weeks and during dose escalations. From SURMOUNT-1 (15 mg arm):
| Side effect | Incidence |
|---|---|
| Nausea | 29% |
| Diarrhea | 23% |
| Constipation | 17% |
| Vomiting | 13% |
| Injection site reaction | 8% |
| Acid reflux | 9% |
About 6% of patients on 15 mg discontinued treatment because of side effects. The rest managed symptoms with diet adjustments and slower titration. For practical management of GI issues, see our piece on why tirzepatide can cause acid reflux.
Less common but more serious risks include pancreatitis (rare, around 0.4% in trials), gallbladder disease (during rapid weight loss), and a black-box warning for medullary thyroid carcinoma based on rodent studies. None of these have shown up at meaningful rates in human data, but the warnings are real.
FAQ
How much weight will I lose on Zepbound in the first month?
Most patients lose 1 to 3% of starting body weight in month 1. Month 1 is the 2.5 mg starter dose, which is a tolerance dose, not a therapeutic dose. Visible change usually starts in months 2 and 3.
How much weight do you lose in 3 months on Zepbound?
Average cumulative loss at month 3 is 7 to 9% of body weight. About two-thirds of patients have lost 5% or more by week 12. This is the point where most patients see noticeable changes in clothes and photos.
How much weight will I lose in 6 months on Zepbound?
Average cumulative loss at month 6 is 14 to 17% on the 15 mg dose. Patients on lower maintenance doses (10 mg) average 11 to 13%.
How much weight will I lose on Zepbound at 1 year?
Average cumulative loss at month 12 is 18 to 20% on 15 mg. The pace slows after month 9, so most of the year-1 loss happens in the first 9 months.
Will I plateau on Zepbound?
Yes, eventually. Most patients reach their personal nadir between months 14 and 18, then plateau within 2% of that nadir. Brief plateaus during titration are normal and not a sign the drug has stopped working.
Why am I not losing weight on Zepbound?
Possibilities include: still on the starter dose (under 8 weeks), eating at maintenance calories despite reduced appetite, fluid retention masking fat loss, concurrent medications that promote weight gain, or being one of the 9% of patients who don't respond meaningfully. If you're past month 3 at a therapeutic dose with no movement, talk with your provider.
Will I gain the weight back if I stop Zepbound?
You'll regain some. SURMOUNT-4 data shows the average patient regains about half of their lost weight within a year off-drug. Some keep most of their loss; some regain almost all. The pattern depends on continued nutrition and exercise habits.
How long can I stay on Zepbound?
Indefinitely is the current clinical answer. Tirzepatide is approved for chronic use in obesity and type 2 diabetes. Long-term safety data extends to about 5 years; the drug behaves like other chronic-disease medications.
Does Zepbound work better than Wegovy?
On average, yes. SURMOUNT-5 head-to-head showed 20.2% loss on tirzepatide vs 13.7% on semaglutide at 72 weeks. Individual responses vary; some patients do better on semaglutide.
Will Zepbound change my face?
Yes, in most patients. Subcutaneous fat in the cheeks and temporal area decreases at a similar rate to whole-body fat loss. The change is usually visible by month 4 and most pronounced by month 9.
Does Zepbound cause loose skin?
Significant weight loss often produces some loose skin, more so in patients losing 25% or more of body weight, in older patients, and in patients with prior weight cycling. Resistance training helps; surgical correction is sometimes considered after weight stabilizes.
Are compounded tirzepatide results the same as Zepbound results?
Compounded tirzepatide contains the same active ingredient as brand-name Zepbound. There are no published head-to-head trials, but pharmacokinetic data suggests comparable efficacy when properly compounded. Quality of compounding varies between pharmacies, so source matters.
How long until I see visible results?
Most patients see clothes fit differently by week 8 to 10. Other people start to comment around month 3. Photos comparing month 0 to month 6 typically show clear visible change.
Author / review note
Reviewed by the FormBlends Medical Team. References cited above include Jastreboff et al., New England Journal of Medicine, 2022 (SURMOUNT-1); Aronne et al., JAMA, 2024 (SURMOUNT-4 maintenance data); Aronne et al., New England Journal of Medicine, 2025 (SURMOUNT-5 head-to-head with semaglutide); and the Endocrine Society 2024 obesity treatment guidelines.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results. Any photos referenced as "before and after" are stock illustrations or trial-data graphics, not actual FormBlends patients.
Trademark Notice. Zepbound, Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →